## Lisa C Silbert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4561898/publications.pdf Version: 2024-02-01



LISA C SUBERT

#	Article	IF	CITATIONS
1	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
2	A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 111-120.	2.6	210
3	Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology, 2013, 81, 977-983.	1.1	179
4	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
5	Peripheral F <sub>2</sub> â€isoprostanes and F <sub>4</sub> â€neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 2002, 52, 175-179.	5.3	156
6	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
7	Cognitive impairment risk. Neurology, 2009, 73, 120-125.	1.1	105
8	Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology, 2012, 79, 741-747.	1.1	102
9	Neuropathologic Basis of Age-Associated Brain Atrophy. JAMA Neurology, 2013, 70, 616.	9.0	90
10	Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time. Neurology, 2018, 90, e2119-e2126.	1.1	69
11	Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: A multi-modal magnetic resonance imaging study. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1528-1536.	4.3	62
12	Aberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 667-676.	1.7	59
13	Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 1587-1597.	2.6	57
14	MR Imaging–based Multimodal Autoidentification of Perivascular Spaces (mMAPS): Automated Morphologic Segmentation of Enlarged Perivascular Spaces at Clinical Field Strength. Radiology, 2018, 286, 632-642.	7.3	56
15	Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins and Other Lipid Mediators, 2014, 113-115, 30-37.	1.9	52
16	Surgery is associated with ventricular enlargement as well as cognitive and functional decline. Alzheimer's and Dementia, 2016, 12, 590-597.	0.8	47
17	Neuroimaging and Cognition in Parkinson's Disease Dementia. Brain Pathology, 2010, 20, 646-653.	4.1	43
18	Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Frontiers in Aging Neuroscience, 2013, 5, 92.	3.4	39

LISA C SILBERT

#	Article	IF	CITATIONS
19	Autoidentification of perivascular spaces in white matter using clinical field strength T1 and FLAIR MR imaging. NeuroImage, 2019, 202, 116126.	4.2	32
20	Biomarker progressions explain higher variability in stageâ€specific cognitive decline than baseline values in Alzheimer disease. Alzheimer's and Dementia, 2014, 10, 690-703.	0.8	31
21	Risk of incident clinical diagnosis of Alzheimer's disease–type dementiaÂattributable to pathologyâ€confirmed vascular disease. Alzheimer's and Dementia, 2017, 13, 613-623.	0.8	30
22	Characterization of MR Imaging–Visible Perivascular Spaces in the White Matter of Healthy Adolescents at 3T. American Journal of Neuroradiology, 2020, 41, 2139-2145.	2.4	28
23	Less Daily Computer Use is Related to Smaller Hippocampal Volumes in Cognitively Intact Elderly. Journal of Alzheimer's Disease, 2016, 52, 713-717.	2.6	27
24	Oxidized Products of Omega-6 and Omega-3 Long Chain Fatty Acids Are Associated with Increased White Matter Hyperintensity and Poorer Executive Function Performance in a Cohort of Cognitively Normal Hypertensive Older Adults. Journal of Alzheimer's Disease, 2020, 74, 65-77.	2.6	25
25	Randomized Trial of Marine n-3 Polyunsaturated Fatty Acids for the Prevention of Cerebral Small Vessel Disease and Inflammation in Aging (PUFA Trial): Rationale, Design and Baseline Results. Nutrients, 2019, 11, 735.	4.1	17
26	Longitudinal MRI-visible perivascular space (PVS) changes with long-duration spaceflight. Scientific Reports, 2022, 12, 7238.	3.3	17
27	Risk Factors Associated with Cortical Thickness and White Matter Hyperintensities in Dementia Free Okinawan Elderly. Journal of Alzheimer's Disease, 2018, 63, 365-372.	2.6	16
28	In-Home Mobility Frequency and Stability in Older Adults Living Alone With or Without MCI: Introduction of New Metrics. Frontiers in Digital Health, 2021, 3, 764510.	2.8	13
29	Unobtrusive Sensing Technology Detects Ecologically Valid Spatiotemporal Patterns of Daily Routines Distinctive to Persons With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2077-2084.	3.6	13
30	The Internet-Based Conversational Engagement Clinical Trial (I-CONECT) in Socially Isolated Adults 75+ Years Old: Randomized Controlled Trial Protocol and COVID-19 Related Study Modifications. Frontiers in Digital Health, 2021, 3, 714813.	2.8	12
31	Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old. Alzheimer Disease and Associated Disorders, 2018, 32, 265-269.	1.3	10
32	GPR39 localization in the aging human brain and correlation of expression and polymorphism with vascular cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12214.	3.7	10
33	Microcephaly Genes and Risk of Late-onset Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2011, 25, 276-282.	1.3	8
34	Can changes in social contact (frequency and mode) mitigate low mood before and during the <scp>COVID</scp> â€19 pandemic? The <scp>lâ€CONECT</scp> project. Journal of the American Geriatrics Society, 2022, 70, 669-676.	2.6	8
35	Depressive symptoms are associated with late life cognitive decline independent of common age-related pathologies. Evidence-Based Mental Health, 2015, 18, 50-50.	4.5	5
36	The "S―in MELAS. Journal of Stroke and Cerebrovascular Diseases, 1996, 6, 67-71.	1.6	3

LISA C SILBERT

#	Article	IF	CITATIONS
37	Does statin use decrease the amount of Alzheimer disease pathology in the brain?. Neurology, 2007, 69, E8-E11.	1.1	2
38	O3â€09â€01: Alzheimer's disease pathology burden associated with clinical dementia decreases with age. Alzheimer's and Dementia, 2012, 8, P446.	0.8	2
39	P4â€514: TRACKING ENLARGED PERIVASCULAR SPACES FROM CLINICAL MRI TO POSTâ€MORTEM MRI GUIDED HISTOPATHOLOGY. Alzheimer's and Dementia, 2019, 15, P1510.	0.8	0
40	Lower average daily step count is associated with poorer executive function and rurality in a veteran cohort. Alzheimer's and Dementia, 2020, 16, e046393.	0.8	0
41	Ageâ€related ventricular expansion is not spatially concordant with MRâ€visible periventricular white matter disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0